Fob1 and Fob2 Proteins Are Virulence Determinants of via Facilitating Iron Uptake from Ferrioxamine

English version České info

Deferoxamine is an iron-chelating agent often used to treat patients with acute iron poisoning, such as seen in dialysis patients with chronic renal failure. These patients are uniquely predisposed to a deadly fungal infection, called mucormycosis, because deferoxamine supplies iron that supports growth of fungi causing this infection. Apart from the important basic knowledge in delineating iron uptake mechanisms in cells, understanding how organisms causing mucormycosis obtain iron from ferrioxamine (deferoxamine bound with iron) is likely to develop strategies to treat mucormycosis infections in patients treated with deferoxamine. In this study we identified two cell surface receptors that bind ferrioxamine and facilitate iron uptake in Rhizopus oryzae, the most causative fungus of mucormycosis. These receptors are required for full virulence of R. oryzae in mice treated with deferoxamine. From genetic and biochemical studies it appears that the fungus binds ferrioxamine via these two receptors then liberates iron through a chemical modification step prior to transporting into the fungal cell without the internalization of deferoxamine.

Vyšlo v časopise: Fob1 and Fob2 Proteins Are Virulence Determinants of via Facilitating Iron Uptake from Ferrioxamine. PLoS Pathog 11(5): e32767. doi:10.1371/journal.ppat.1004842
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004842

Souhrn

Zdroje

1. Ibrahim AS, Edwards JE Jr., Filler SG, Spellberg B (2011) Mucormycosis and Entomophtoramycosis (Zygomycosis). In: Kauffman CA PP, Sobel JD, Dismukes WE, 2nd Ed., editor. Essentials of Clinical Mycology. New York: Springer. pp. 265–280.

2. Kontoyiannis DP, Lewis RE (2006) Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 20: 581–607, vi. 16984870

3. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, et al. (2009) Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 15: 1395–1401. doi: 10.3201/eid1509.090334 19788806

4. Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, et al. (2009) Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 85: 573–581. doi: 10.1136/pgmj.2008.076463 19892892

5. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E (2004) Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 45: 1351–1360. 15359632

6. Ibrahim AS (2011) Host cell invasion in mucormycosis: role of iron. Curr Opin Microbiol 14: 406–411. doi: 10.1016/j.mib.2011.07.004 21807554

7. Kauffman CA (2004) Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 39: 588–590. 15356828

8. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV (2000) Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 30: 851–856. 10852735

9. Ibrahim AS, Spellberg B, Edwards J Jr. (2008) Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21: 620–625. doi: 10.1097/QCO.0b013e3283165fd1 18978530

10. Sugar AM (2005) Agents of Mucormycosis and Related Species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Elsevier. pp. 2979.

11. Artis WM, Fountain JA, Delcher HK, Jones HE (1982) A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 31: 1109–1114. 6816646

12. Walsh TJ, Bloom BE, Kontoyiannis DP (2012) Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis. Clin Infect Dis 54 Suppl 1: S1–4. doi: 10.1093/cid/cir862 22247440

13. Boelaert JR (1994) Mucormycosis (zygomycosis): is there news for the clinician? Journal of Infection 28 Suppl 1: 1–6. 8077686

14. Boelaert JR, Fenves AZ, Coburn JW (1989) Registry on mucormycosis in dialysis patients [letter]. Journal of Infectious Diseases 160: 914. 2809271

15. Boelaert JR, van Roost GF, Vergauwe PL, Verbanck JJ, de Vroey C, et al. (1988) The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clinical Nephrology 29: 261–266. 3293856

16. Boelaert JR, Vergauwe PL, Vandepitte JM (1987) Mucormycosis infection in dialysis patients [letter]. Annals of Internal Medicine 107: 782–783. 3662297

17. Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, et al. (1993) Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. Journal of Clinical Investigation 91: 1979–1986. 8486769

18. de Locht M, Boelaert JR, Schneider YJ (1994) Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochemical Pharmacology 47: 1843–1850. 8204101

19. Ibrahim AS, Edwards JE Jr., Fu Y, Spellberg B (2006) Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 58: 1070–1073. 16928702

20. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, et al. (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117: 2649–2657. 17786247

21. Maruyama HB, Azuma H, Koto Y, Suhara Y (1975) Desferrioxamine B, an inhibitor of Escherichia coli motility, reversing the stimulating effect of cyclic adenosine 3',5'-monophosphate. Antimicrob Agents Chemother 7: 377–380. 166612

22. Thieken A, Winkelmann G (1992) Rhizoferrin: a complexone type siderophore of the Mucorales and entomophthorales (Zygomycetes). FEMS Microbiol Lett 73: 37–41. 1387861

23. Kwon-Chung KJ, Bennett JE (1992) Mucormycosis. Medical Mycology. Philadelphia: Lea & Febiger. pp. 524–559.

24. Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, et al. (2010) The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 77: 587–604. doi: 10.1111/j.1365-2958.2010.07234.x 20545847

25. Yun CW, Ferea T, Rashford J, Ardon O, Brown PO, et al. (2000) Desferrioxamine-mediated iron uptake in Saccharomyces cerevisiae. Evidence for two pathways of iron uptake. J Biol Chem 275: 10709–10715. 10744769

26. Yun CW, Tiedeman JS, Moore RE, Philpott CC (2000) Siderophore-iron uptake in Saccharomyces cerevisiae. Identification of ferrichrome and fusarinine transporters. J Biol Chem 275: 16354–16359. 10748025

27. Lesuisse E, Simon-Casteras M, Labbe P (1998) Siderophore-mediated iron uptake in Saccharomyces cerevisiae: the SIT1 gene encodes a ferrioxamine B permease that belongs to the major facilitator superfamily. Microbiology 144 (Pt 12): 3455–3462. 9884238

28. Heymann P, Gerads M, Schaller M, Dromer F, Winkelmann G, et al. (2002) The siderophore iron transporter of Candida albicans (Sit1p/Arn1p) mediates uptake of ferrichrome-type siderophores and is required for epithelial invasion. Infect Immun 70: 5246–5255. 12183576

29. Moore RE, Kim Y, Philpott CC (2003) The mechanism of ferrichrome transport through Arn1p and its metabolism in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 100: 5664–5669. 12721368

30. Philpott CC, Protchenko O (2008) Response to iron deprivation in Saccharomyces cerevisiae. Eukaryot Cell 7: 20–27. 17993568

31. Boelaert JR, Fenves AZ, Coburn JW (1989) Mucormycosis among patients on dialysis [letter]. New England Journal of Medicine 321: 190–191. 2747752

32. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR (1994) Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney International 45: 667–671. 8196268

33. Pitarch A, Nombela C, Gil C (2008) Collection of proteins secreted from yeast protoplasts in active cell wall regeneration. Methods Mol Biol 425: 241–263. doi: 10.1007/978-1-60327-210-0_20 18369901

34. Ignoul S, Eggermont J (2005) CBS domains: structure, function, and pathology in human proteins. Am J Physiol Cell Physiol 289: C1369–1378. 16275737

35. Jentsch TJ, Neagoe I, Scheel O (2005) CLC chloride channels and transporters. Curr Opin Neurobiol 15: 319–325. 15913981

36. Kemp BE (2004) Bateman domains and adenosine derivatives form a binding contract. J Clin Invest 113: 182–184. 14722609

37. McLean JE, Hamaguchi N, Belenky P, Mortimer SE, Stanton M, et al. (2004) Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo. Biochem J 379: 243–251. 14766016

38. Aguado-Llera D, Oyenarte I, Martinez-Cruz LA, Neira JL (2010) The CBS domain protein MJ0729 of Methanocaldococcus jannaschii binds DNA. FEBS Lett 584: 4485–4489. doi: 10.1016/j.febslet.2010.10.006 20934423

39. Ishitani R, Sugita Y, Dohmae N, Furuya N, Hattori M, et al. (2008) Mg2+-sensing mechanism of Mg2+ transporter MgtE probed by molecular dynamics study. Proc Natl Acad Sci U S A 105: 15393–15398. doi: 10.1073/pnas.0802991105 18832160

40. Stintzi A, Barnes C, Xu J, Raymond KN (2000) Microbial iron transport via a siderophore shuttle: a membrane ion transport paradigm. Proc Natl Acad Sci U S A 97: 10691–10696. 10995480

41. Braun V, Hantke K, Koster W (1998) Bacterial iron transport: mechanisms, genetics, and regulation. Met Ions Biol Syst 35: 67–145. 9444760

42. Cole G, Simonetti K, Ademi I, Sharpe S (2012) Dimerization of the transmembrane domain of human tetherin in membrane mimetic environments. Biochemistry 51: 5033–5040. doi: 10.1021/bi201747t 22667354

43. Columbus L, Lipfert J, Klock H, Millett I, Doniach S, et al. (2006) Expression, purification, and characterization of Thermotoga maritima membrane proteins for structure determination. Protein Sci 15: 961–975. 16597824

44. Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, et al. (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol 125: 549–564. doi: 10.1007/s00401-013-1083-z 23354835

45. Lisiecki P, Wysocki P, Mikucki J (1999) [Hydroxamate siderophores in enterococci]. Med Dosw Mikrobiol 51: 249–257. 10803254

46. Lisiecki P, Wysocki P, Mikucki J (2000) Occurrence of siderophores in enterococci. Zentralbl Bakteriol 289: 807–815. 10705612

47. Muller G, Raymond KN (1984) Specificity and mechanism of ferrioxamine-mediated iron transport in Streptomyces pilosus. J Bacteriol 160: 304–312. 6480557

48. Protchenko O, Ferea T, Rashford J, Tiedeman J, Brown PO, et al. (2001) Three cell wall mannoproteins facilitate the uptake of iron in Saccharomyces cerevisiae. J Biol Chem 276: 49244–49250. 11673473

49. de Locht M, Boelaert JR, Schneider YJ (1994) Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 47: 1843–1850. 8204101

50. Kuhn S, Braun V, Koster W (1996) Ferric rhizoferrin uptake into Morganella morganii: characterization of genes involved in the uptake of a polyhydroxycarboxylate siderophore. J Bacteriol 178: 496–504. 8550472

51. Schaller M, Korting HC, Schafer W, Bastert J, Chen W, et al. (1999) Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 34: 169–180. 10540295

52. Gutteridge JM, Quinlan GJ, Swain J, Cox J (1994) Ferrous ion formation by ferrioxamine prepared from aged desferrioxamine: a potential prooxidant property. Free Radic Biol Med 16: 733–739. 8070676

53. Fu Y, Lee H, Collins M, Tsai HF, Spellberg B, et al. (2004) Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett 235: 169–176. 15158278

54. Howard DH (1999) Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev 12: 394–404. 10398672

55. Lesuisse E, Labbe P (1989) Reductive and non-reductive mechanisms of iron assimilation by the yeast Saccharomyces cerevisiae. J Gen Microbiol 135: 257–263. 11699493

56. Larcher G, Dias M, Razafimandimby B, Bomal D, Bouchara JP (2013) Siderophore production by pathogenic mucorales and uptake of deferoxamine B. Mycopathologia 176: 319–328. doi: 10.1007/s11046-013-9693-5 23982284

57. Skory CD, Ibrahim AS (2007) Native and modified lactate dehydrogenase expression in a fumaric acid producing isolate Rhizopus oryzae 99-880. Curr Genet 52: 23–33. 17551728

58. Dertz EA, Stintzi A, Raymond KN (2006) Siderophore-mediated iron transport in Bacillus subtilis and Corynebacterium glutamicum. J Biol Inorg Chem 11: 1087–1097. 16912897

59. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101–1108. 18546601

60. Skory CD (2003) Induction of Rhizopus oryzae pyruvate decarboxylase genes. Curr Microbiol 47: 59–64. 12783195

61. Dancis A, Klausner RD, Hinnebusch AG, Barriocanal JG (1990) Genetic evidence that ferric reductase is required for iron uptake in Saccharomyces cerevisiae. Mol Cell Biol 10: 2294–2301. 2183029

62. Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG, et al. (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73: 999–1005. 15664943

63. Fu Y, Ibrahim AS, Sheppard DC, Chen YC, French SW, et al. (2002) Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol 44: 61–72. 11967069

64. Abe F, Inaba H, Katoh T, Hotchi M (1990) Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 110: 87–91. 2142253

65. Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, et al. (2014) CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest 124: 237–250. doi: 10.1172/JCI71349 24355926

66. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr. (2003) Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 47: 3343–3344. 14506054

67. Liu M, Spellberg B, Phan QT, Fu Y, Lee AS, et al. (2010) The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 120: 1914–1924. doi: 10.1172/JCI42164 20484814

68. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, et al. (2005) Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 49: 721–727. 15673756

69. Aso H, Miyoshi S, Nakao H, Okamoto K, Yamamoto S (2002) Induction of an outer membrane protein of 78 kDa in Vibrio vulnificus cultured in the presence of desferrioxamine B under iron-limiting conditions. FEMS Microbiol Lett 212: 65–70. 12076789